Connect Biopharma Holdings (CNTB) Total Liabilities (2020 - 2026)

Connect Biopharma Holdings (CNTB) has reported Total Liabilities for 7 consecutive years, with $17.4 million the latest figure, recorded in Q1 2026.

• Quarterly Total Liabilities rose 78.24% year-over-year to $17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.4 million (up 78.24% YoY) and the FY2025 annual result came in at $14.1 million, up 54.58% from the prior year.
• Total Liabilities advanced to $17.4 million in Q1 2026 per CNTB's latest filing, from $14.1 million in the prior quarter.
• Over the last five years, Total Liabilities for CNTB reached as high as $25.9 million in Q4 2023 and fell as low as $9.1 million in Q4 2024.
• A 5-year average of $14.8 million and a median of $14.1 million in 2025 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities plunged 64.77% — and 2026, when it soared 78.24%.
• Year by year, Total Liabilities stood at $16.2 million in 2022, then soared by 59.96% to $25.9 million in 2023, then tumbled by 64.77% to $9.1 million in 2024, then soared by 54.58% to $14.1 million in 2025, then rose by 23.75% to $17.4 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $17.4 million, $14.1 million, and $12.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.